NCT04371276 is a clinical trial of No intervention in Viral Hepatitis, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT04371276?

NCT04371276 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT04371276?

Interventions in NCT04371276: No intervention.

What condition does NCT04371276 study?

NCT04371276 studies Viral Hepatitis.

Is NCT04371276 still recruiting?

NCT04371276 is currently completed. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT04371276

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Seroepidemiology of Viral Hepatitis in Hong Kong

Completed Last updated 8 February 2023

What this trial tests

trial testing No intervention in Viral Hepatitis in 2,888 participants. Completed in 31 May 2022.

Timeline

1 September 2018

Primary endpoint
31 December 2021

31 May 2022

Quick facts

Lead sponsor	Chinese University of Hong Kong
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,888
Start date	1 September 2018
Primary completion	31 December 2021
Estimated completion	31 May 2022
Sites	1 location across China

Drugs / interventions tested

No intervention

Conditions studied

Viral Hepatitis — all drugs for Viral Hepatitis →

Sponsor

Chinese University of Hong Kong

Who can join

Eligibility, any sex, with Viral Hepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Immunisation policies have strong influences on the epidemiology of hepatitis A and B infection. In Hong Kong, vaccines against both viruses have been available through different channels and programmes in the past 3 decades. To evaluate the changes in the prevalence of hepatitis A and B in the general population, a seroepidemiology study is conducted involving a prospective cross-sectional survey followed for serology testing. Eligible members of 1327 spatially random households would be invited to join the study by completing a questionnaire and providing blood samples, either by dried blood spots or venesection, for determining the presence of antigen and/or antibody against hepatitis B, as well as antibody against hepatitis A. The main measures comprise a set of metrics on the prevalence of hepatitis A and B. Analysis would be conducted to examine the association of risk factors with the tested markers and describe the attitudes towards viral hepatitis vaccination. The results would allow us to understand the transmission potential of hepatitis A and B in the community would be influenced by the changing disease epidemiology and coverage of vaccination, which inform the development of new vaccination strategies in Hong Kong

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Seroepidemiology of hepatitis A and B in the general population in Hong Kong: protocol of a cross-sectional survey using spatial sampling in a highly urbanised city.
Poon CM, Chan DP, Lee SS, Wong NS. · · 2021 · cited 5× · PMID 33753433 · DOI 10.1136/bmjopen-2020-042065

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting

Other recruiting trials for Viral Hepatitis

Currently open trials in the same condition.

NCT06904820 — Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable · recruiting
NCT03933384 — Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B · Phase 4 · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04371276 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04371276.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing